he Pioneer in Evidence-Based Healthcare is Expanding its Award-Winning Platform to Life Sciences; Appoints Two Industry Leaders to New Life Sciences Advisory Board
PALO ALTO, CA – Aug. 24, 2023 – Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, today announced its entry into the life sciences sector. Serving its mission to inform every clinical decision and research inquiry with rapid real-world evidence, the company extends its award-winning Evidence Platform to applications across life sciences – analytics augmentation, faster data evaluation, evidence generation, and artificial intelligence innovations. Guiding this expansion is a newly-appointed Life Science Advisory Board, whose inaugural members are Sean Khozin MD, MPH and Gerry McDougall. The board will advance Atropos Health’s aim to resolve high priority business needs with evidence from real-world data.
“Evidence production is the lifeblood of the life sciences business. With Atropos Evidence Platform researchers can dramatically expand and accelerate their evidence generation capabilities – while maximizing productivity of existing headcount and reducing need for outsourced staffing. Additionally, Atropos Evidence Network allows researchers to rapidly generate evidence from many data sources without extensive onboarding or infrastructure hurdles,”
– Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health.
Beginning today, life science users can access a specialized version of the “Green Button.” The Green Button combines the Evidence Platform’s technologies with clinical informatics support to generate evidence in 48 hours in a private library. This enables life science companies to maximize their real-world data assets for iterative hypothesis testing, protocol feasibility, cohort analysis, treatment pathways, patient journeys, unmet need, label expansion, and regulatory initiatives.
Evidence may be produced from customers’ cloud-based in-house data platforms behind their firewall, adding to the value of their existing infrastructure investments, or from external data via Atropos Evidence™ Network. This offers a secure mechanism to expand information access and study capabilities. Resulting outputs receive Real World Fitness Scores (RWFS™) that score dataset suitability for each study. Atropos Health’s data scoring solutions are shifting paradigms in data strategy, feasibility, activation, and ROI. With these new data access and scoring solutions, life science teams can identify “fit-for-purpose” data, use it for faster analyses, and validate with clinical perspectives – tackling many of the greatest challenges to evidence generation.
“Atropos Health provides immediate insights based on the real-world experience of individual patients. This can help new therapies reach safety-efficacy targets in a shorter time frame and in smaller studies that are optimized for clinical benefit, by selecting the right patients using features extracted from RWD. At a time when clinical development costs have steadily increased against a backdrop of downward pressure on drug pricing, the ability to quickly and accurately develop new precision medicines that address unmet patient needs requires focus and alignment from bench to bedside.”
– Dr. Sean Khozin MD, former FDA official and Atropos Health Life Sciences Advisor
With its expansion into the life sciences market, Atropos Health redoubles its commitment to building the future of evidence-based medicine – with personalized evidence for every clinical decision and research inquiry. This announcement follows various strategic partnerships and a health system ROI study that demonstrated more than $3M in institutional savings potential from one year of using the Atropos Evidence Platform.
“In my three plus decades in the industry I have never seen such an efficient use of real world evidence applications. Atropos Evidence Platform powers early-stage to post market studies in days, illuminates the complex interplay of patient characteristics and therapeutic performance, and delivers the tools for the connected learning health system we have sought for decades. I am eager to help this potential be realized.”
– Gerry McDougall, Atropos Health Life Science Advisor
About Atropos Health
Atropos Health is the developer of Atropos Evidence™ Platform, a catalyst for evidence generation across a vast network of real world data. Healthcare organizations and life science companies leverage our platform to close evidence gaps from bench to bedside, elevate patient outcomes with data-driven care, expedite research, and more. Atropos Health’s offerings are based upon dozens of peer-reviewed publications, years of clinical use, and clinical expertise. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on Twitter @AtroposHealth.
Source: https://www.atroposhealth.com/blog/life-science-launch-ad-board